罗格列酮钠联合阿司匹林治疗糖尿病伴代谢综合征的临床研究  

Clinical trial of rosiglitazone sodium combined with aspirin in the treatment of patients with diabetes mellitus and metabolic syndrome

作　　者：张蕴颖[1] 孙霞[2] 鲍黎明[3] ZHANG Yun-ying;SUN Xia;BAO Li-ming(Department of Endocrinology;Department of Endocrine;Department of Radiation,Lishui Central Hospital,lishui 323000,Zhejiang Province,China)

机构地区：[1]丽水市中心医院体检中心,浙江丽水323000 [2]丽水市中心医院内分泌科,浙江丽水323000 [3]丽水市中心医院放疗科,浙江丽水323000

出　　处：《中国临床药理学杂志》2018年第17期2073-2076,共4页The Chinese Journal of Clinical Pharmacology

基　　金：浙江省卫生和计划生育委员会基金资助项目(2017KY729)

摘　　要：目的研究罗格列酮钠联合阿司匹林治疗糖尿病伴代谢综合征的疗效。方法选取本院收治的糖尿病伴代谢综合征患者68例,按随机数表法将患者分对照组34例和试验组34例。对照组患者口服盐酸二甲双胍缓释片,每次0.5g,每天1次;在对照组的基础上,试验组患者口服阿司匹林肠溶片100 mg·d^(-1)和口服罗格列酮钠4 mg·d^(-1)。2组均治疗1个月,1个月为一个疗程。用化学发光法测定超敏C反应蛋白(hs-CRP)水平;以酶联免疫吸附试验测定血清趋化素、脂联素与内脂素水平。结果治疗后,试验组和对照组体重指数(BMI)分别为(23.16±1.53),(24.61±1.85)kg·m^(-2);这2组的血清趋化素水平分别为(75.39±8.21),(80.16±8.54)ng·m L^(-1);这2组的血清Hs-CRP分别为(1.54±1.03),(0.92±0.87)mg·L^(-1);这2组的脂联素分别为(2.13±0.95),(1.46±0.89)μg·L^(-1);这2组的血清内脂素分别为(69.13±8.12),(62.30±7.75)μg·L^(-1),2组治疗后与治疗前比较,差异均有统计学意义(均P<0.05);治疗后,试验组与对照组比较,差异均有统计学意义(均P<0.05)。结论罗格列酮钠与阿司匹林可协同改善糖尿病伴代谢综合征与胰岛素抵抗,减轻患者体重。Objective To investigate the effect of rosiglitazone sodium combined with aspirin in the treatment of patients with diabetes mellitus and metabolic syndrome（ DMMS）. Methods Sixty eight cases of DMMS were randomly divided into control group and treatment group with 34 cases in each group. Patients in the control group were given metformin hydrochloride orally,0. 5 g each time,1 times a day; on the basis of control group,treatment group was given oral aspirin 100 mg·d^（-1） and rosiglitazone sodium 4 mg·d^（-1） orally,two groups were treated for 1 months for a course of treatment. The level of the hypersensitive C-reactive protein（ Hs-CRP） was determined by chemiluminescence. The levels of the Chemerin,adiponectin,Visfatin were determined by enzyme linked immunosorbent assay. Results After treatment,the body mass index（ BMI） in the treatment group and control group were（ 23. 16 ± 1. 53）,（ 24. 61 ± 1. 85） kg · m^（-2）; the Chemerin in the 2 groups were（ 75. 39 ± 8. 21）,（ 80. 16 ± 8. 54） ng · m L^（-1）; the Hs-CRP in the 2 groups were（ 1. 54 ± 1. 03）,（ 0. 92 ± 0. 87） mg · L^（-1）; the serumadiponectin in the 2 groups were（ 2. 13 ± 0. 95）,（ 1. 46 ± 0. 89） μg · L^（-1）; visfatin in the 2 groups were（ 69. 13 ± 8. 12）,（ 62. 30 ± 7. 75） μg·L^（-1）. Comparison between before and after treatment,the difference of the factors had statistical significantly（ all P〈 0. 05）. Comparison between treatment group and control grou,the difference of the factors had statistical significantly（ all P〈 0. 05）. Conclusion Rosiglitazone sodium and aspirin can synergistically improve DMMS insulin resistance,reduce the body mass of the patients.

关 键 词：罗格列酮钠 阿司匹林 糖尿病 代谢综合征 

分 类 号：R977.15[医药卫生—药品]